Roche heirs bid goodbye to ‘unsustainable’ philanthropy
The heirs of Switzerland’s pharmaceutical company Roche are ending an era as philanthropic donors for major nature conservation projects, the NZZ am Sonntag reported.
This content was published on
2 minutes
Русский
ru
Концерн Roche прощается с «нерентабельной» филантропией
Their Mava Foundation, established 25 years ago, will shut down next year. “The traditional form of philanthropy has failed,” Roche Vice Chairman Andre Hoffmann told the German-language weekly in an interview published on Sunday.
Transferring money because you have a guilty conscience doesn’t do any good, the 63-year-old foundation president and economist explained.
“You may feel good about it yourself, but it doesn’t solve the problems,” he said. “Projects that exist only as long as we pay and stop when we withdraw are misguided.”
At last count, the Mava Foundation was involved in 180 projects with 120 partners. Many managed to continue and survive on their own, according to Hoffmann, spokesman for the Roche shareholder pool.
The foundation’s closure has been in the works for years.
Founded in 1994
The foundation, based in the town of Gland, canton Vaud, had been established in 1994. Launched by Hoffmann’s father, Luc, its original aim was to protect unique landscapes such as the Camargue.
Hoffmann told the newspaper he and his children would continue to support projects provided that they are based on a business model that ensured survival.
“The success of a project should not depend on the donor,” he stressed.
Hoffmann, who is involved in more than a dozen charitable activities, also called for greater accountability from companies when consumption of their products causes harm.
Food manufacturers, for example, should have to answer for health damage caused by excessive sugar content in their products, he said.
Greenwashing
He also criticised the way many companies still develop products without paying attention to their ecological footprint. It is only later that something is donated.
These companies, he argues, are guilty of greenwashing. “It’s not how you spend the money that matters, it’s how you do it,” he said.
Hoffmann believes the financial industry has the highest potential to make an impact because “it determines where the capital of pension funds and other investors goes”.
Protein in abdominal fat could help shape obesity treatment
This content was published on
The study analysed fat cells from different locations in the body, and found that those in the abdomen have unique properties.
North African asylum claims fall after rapid Swiss processing
This content was published on
The accelerated procedure, now out of its test phase, has resulted in a significant drop in applications from North African countries.
This content was published on
The artist's song "The Code" focuses on their journey as a nonbinary individual. It is one of the favourites to win this year's contest.
Swiss climate activists block vehicles near Gotthard tunnel
This content was published on
Around ten climate activists briefly blocked the A2 motorway near the northern entrance of the Gotthard tunnel on Thursday.
Watches belonging to Michael Schumacher up for auction
This content was published on
Schumacher's family is auctioning off eight rare watches from his collection in Geneva. The Christie's auction will take place on Monday.
Joya Marleen and Baschi named best solo acts at Swiss Music Awards
This content was published on
St. Gallen singer Joya Marleen and Baschi from Basel were named artists of the year at the Swiss Music Awards 2024 on Wednesday night.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Eight Swiss in Bloomberg billionaire ‘rich list’
This content was published on
In the latest version of the Bloomberg Billionaires Index, eight Swiss or Swiss-resident names figure among the 500 richest people in the world.
Swiss pharma industry fights lower drug prices in the US
This content was published on
A proposed US law aims to lower prescription drug prices. But Big Pharma is pulling out all the stops to lobby against it.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.